Phase III Trials In Glioblastoma Multiforme
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Drug development for the complex, rare and aggressive orphan cancer glioblastoma multiforme is fraught with challenges and few compounds make it through registrational studies. Contenders in the space include Roche/Genentech's Avastin (bevacizumab) and EMD Serono's cilengitide. Research aimed at making better use of one of the few drugs that is approved and used in GBM - Merck's standard-of-care treatment Temodar (temozolomide) - is also ongoing. Sources: Elsevier Business Intelligence's Inteleos drug development database, www.clinicaltrials.gov, company websites.